{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T22:33:11Z","timestamp":1790289191621,"version":"4.1.0"},"reference-count":50,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2024,3,6]],"date-time":"2024-03-06T00:00:00Z","timestamp":1709683200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Michael E. DeBakey VA medical center in Houston, TX"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmacy"],"abstract":"<jats:p>Background: Opioid-induced constipation (OIC) is a pervasive and distressing side effect of chronic opioid therapy in patients with cancer pain, significantly impacting their quality of life. Peripherally acting \u03bc-opioid receptor antagonists (PAMORAS) were developed for treatment-resistant OIC but most studies were conducted with non-cancer patients. Objective: to discuss two oral formulations of PAMORAs, naldemedine and naloxegol, and to review available evidence of the effectiveness of these drugs for OIC in cancer patients. Methods: a comprehensive search to identify primary literature for either naldemedine or naloxegol for OIC in cancer patients. Results: Only three prospective randomized, double-blind, placebo-controlled clinical trials for naldemedine enrolling cancer patients were identified; the results of a subgroup analysis of two of those studies and two non-interventional post marketing surveillance studies of these trials are also reported here. For naloxegol, only two randomized controlled trials were identified; both were unsuccessful in enrolling sufficient patients. An additional four prospective non-interventional observational studies with naloxegol were found that enrolled cancer patients. There were significantly higher rates of responders in the PAMORA groups than in the placebo groups. The most common side effect for both PAMORAs was diarrhea. Limitations: All studies were industry-funded, and given that only three trials were randomized controlled studies, the overall quality of the studies was lacking. Conclusion: Naldemedine or naloxegol appeared safe and useful in the treatment of OIC in cancer patients and may improve their quality of life. Larger-scale randomized placebo-controlled studies of PAMORAs in cancer patients would strengthen existing evidence.<\/jats:p>","DOI":"10.3390\/pharmacy12020048","type":"journal-article","created":{"date-parts":[[2024,3,7]],"date-time":"2024-03-07T08:59:37Z","timestamp":1709801977000},"page":"48","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["A Systematic Review of Naldemedine and Naloxegol for the Treatment of Opioid-Induced Constipation in Cancer Patients"],"prefix":"10.3390","volume":"12","author":[{"given":"Ursula K.","family":"Braun","sequence":"first","affiliation":[{"name":"Rehabilitation & Extended Care Line, Michael E. DeBakey VA Medical Center, Houston, TX 77030, USA"},{"name":"Section of Geriatrics & Palliative Medicine, Baylor College of Medicine, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leanne K.","family":"Jackson","sequence":"additional","affiliation":[{"name":"Rehabilitation & Extended Care Line, Michael E. DeBakey VA Medical Center, Houston, TX 77030, USA"},{"name":"Section of Geriatrics & Palliative Medicine, Baylor College of Medicine, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-6627-2697","authenticated-orcid":false,"given":"Mary A.","family":"Garcia","sequence":"additional","affiliation":[{"name":"Rehabilitation & Extended Care Line, Michael E. DeBakey VA Medical Center, Houston, TX 77030, USA"},{"name":"Section of Geriatrics & Palliative Medicine, Baylor College of Medicine, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syed N.","family":"Imam","sequence":"additional","affiliation":[{"name":"Section of Geriatrics & Palliative Medicine, Baylor College of Medicine, Houston, TX 77030, USA"},{"name":"Office of Connected Care, Michael E. DeBakey VA Medical Center, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,3,6]]},"reference":[{"key":"ref_1","first-page":"579","article-title":"Analgesic drugs","volume":"13","author":"Rang","year":"1999","journal-title":"Pharmacology"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"649","DOI":"10.2165\/00003495-200363070-00003","article-title":"Opioid-induced bowel dysfunction: Pathophysiology and potential new therapies","volume":"63","author":"Kurz","year":"2003","journal-title":"Drugs"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1191\/026921698674125048","article-title":"The relationship between opioid use and laxative use in terminally ill cancer patients","volume":"12","author":"Sykes","year":"1998","journal-title":"Palliat. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/j.1526-4637.2008.00495.x","article-title":"The prevalence, severity, and impact of opioid-induced bowel dysfunction: Results of a US and European Patient Survey (PROBE 1)","volume":"10","author":"Bell","year":"2009","journal-title":"Pain Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1053\/j.gastro.2016.03.035","article-title":"Rome IV-Functional GI disorders: Disorders of gut-brain interaction","volume":"150","author":"Drossman","year":"2016","journal-title":"Gastroenterology"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"151","DOI":"10.5056\/jnm16214","article-title":"What is New in Rome IV","volume":"23","author":"Schmulson","year":"2017","journal-title":"J. Neurogastroenterol. Motil."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1177\/0897190017732263","article-title":"Peripherally Acting \u03bc-Opioid Receptor Antagonists for the Treatment of Opioid-Related Side Effects: Mechanism of Action and Clinical Implications","volume":"31","author":"Streicher","year":"2017","journal-title":"J. Pharm. Pract."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.2165\/11634970-000000000-00000","article-title":"Opioid Induced Bowel Dysfunction","volume":"72","author":"Brock","year":"2012","journal-title":"Drugs"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1124\/jpet.116.239061","article-title":"Pharmacologic Profile of Naloxegol, a Peripherally Acting \u00b5-Opioid Receptor Antagonist, for the Treatment of Opioid-Induced Constipation","volume":"361","author":"Floettmann","year":"2017","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_10","first-page":"601","article-title":"Naldemedine (Symproic) for the Treatment of Opioid-Induced Constipation","volume":"43","author":"Hu","year":"2018","journal-title":"Pharm. Ther."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s40265-015-0357-2","article-title":"Naloxegol: A review of its use in patients with opioid-induced constipation","volume":"75","year":"2015","journal-title":"Drugs"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Essmat, N., Kar\u00e1di, D.\u00c1., Z\u00e1dor, F., Kir\u00e1ly, K., F\u00fcrst, S., and Al-Khrasani, M. (2023). Insights into the Current and Possible Future Use of Opioid Antagonists in Relation to Opioid-Induced Constipation and Dysbiosis. Molecules, 28.","DOI":"10.3390\/molecules28237766"},{"key":"ref_13","unstructured":"FDA (2023, November 28). Symproic (Naldemedine) Tablets, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2017\/208854Orig1s000TOC.cfm."},{"key":"ref_14","unstructured":"FDA (2023, November 28). Movantik (Naloxegol) Prescribing Information Highlights (PDF), Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/204760s000lbl.pdf."},{"key":"ref_15","unstructured":"European Medicines Agency (EMA) (2024, February 07). \u201cRizmoic: EPAR\u2014Product Information\u201d (PDF). Available online: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/rizmoic-epar-product-information_en.pdf."},{"key":"ref_16","unstructured":"European Medicines Agency (EMA) (2024, January 31). \u201cMoventig\u201d: EPAR\u2014Product Information (PDF). Available online: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/moventig-epar-product-information_en.pdf."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1053\/j.gastro.2018.07.016","article-title":"American Gastroenterological Association Institute Guideline on the Medical Management of Opioid-Induced Constipation","volume":"156","author":"Crockett","year":"2019","journal-title":"Gastroenterology"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"iv111","DOI":"10.1093\/annonc\/mdy148","article-title":"ESMO Guidelines Committee. Diagnosis, assessment and management of constipation in advanced cancer: ESMO Clinical Practice Guidelines","volume":"29","author":"Larkin","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1177\/2050640618818305","article-title":"Pathophysiology and management of opioid-induced constipation: European expert consensus statement","volume":"7","author":"Farmer","year":"2019","journal-title":"United Eur. Gastroenterol. J."},{"key":"ref_20","unstructured":"(2023, November 28). Schedules of Controlled Substances: Removal Of Naldemedine from Control (PDF). Federal Register, Available online: https:\/\/www.govinfo.gov\/content\/pkg\/FR-2017-07-12\/pdf\/2017-14482.pdf."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1007\/s40262-016-0479-z","article-title":"Clinical Pharmacokinetics and Pharmacodynamics of Naloxegol, a Peripherally Acting \u00b5-Opioid Receptor Antagonist","volume":"56","author":"Bui","year":"2017","journal-title":"Clin. Pharmacokinet."},{"key":"ref_22","unstructured":"(2023, November 28). Federal Register, Available online: https:\/\/www.federalregister.gov\/documents\/2015\/01\/23\/2015-01172\/schedules-of-controlled-substances-removal-of-naloxegol-from-control."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"e13563","DOI":"10.1111\/nmo.13563","article-title":"Pharmacologic effects of naldemedine, a peripherally acting \u03bc-opioid receptor antagonist, in in vitro and in vivo models of opioid-induced constipation","volume":"31","author":"Kanemasa","year":"2019","journal-title":"Neurogastroenterol. Motil"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1002\/cpdd.690","article-title":"The Influence of Renal or Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of Naldemedine","volume":"9","author":"Fukumura","year":"2020","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1002\/jcph.348","article-title":"The effects of mild or moderate hepatic impairment on the pharmacokinetics, safety, and tolerability of naloxegol","volume":"54","author":"Bui","year":"2014","journal-title":"J. Clin. Pharmacol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"605","DOI":"10.2147\/JPR.S237833","article-title":"A Renal Impairment Subgroup Analysis of the Safety and Efficacy of Naldemedine for the Treatment of Opioid-Induced Constipation in Patients with Chronic Non-Cancer Pain Receiving Opioid Therapy","volume":"13","author":"Webster","year":"2020","journal-title":"J. Pain Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1002\/jcph.349","article-title":"The effects of renal impairment on the pharmacokinetics, safety, and tolerability of naloxegol","volume":"54","author":"Bui","year":"2014","journal-title":"J. Clin. Pharmacol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s40266-020-00753-2","article-title":"Safety and Efficacy of Naldemedine for the Treatment of Opioid-Induced Constipation in Patients with Chronic Non-Cancer Pain Receiving Opioid Therapy: A Subgroup Analysis of Patients \u2265 65 Years of Age","volume":"37","author":"Wild","year":"2020","journal-title":"Drugs Aging"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Kamiya, T., Imai, H., Fujita, Y., Hiruta, E., Masuno, T., Yamazaki, S., Tanaka, H., Sandoh, M., Takei, S., and Arai, K. (2023). A Retrospective Study of the Efficacy and Safety of Naldemedine for Treatment of Opioid-Induced Constipation in Patients with Hepatobiliary Pancreatic Cancer. Medicina, 59.","DOI":"10.3390\/medicina59030492"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/S2468-1253(17)30105-X","article-title":"Naldemedine versus placebo for opioid-induced constipation (COMPOSE-1 and COMPOSE-2): Two multicentre, phase 3, double-blind, randomised, parallel-group trials","volume":"2","author":"Hale","year":"2017","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.2147\/JPR.S282738","article-title":"Naldemedine Improves Patient-Reported Outcomes of Opioid-Induced Constipation in Patients with Chronic Non-Cancer Pain in the COMPOSE Phase 3 Studies","volume":"14","author":"Camilleri","year":"2021","journal-title":"J. Pain Res."},{"key":"ref_32","unstructured":"von Roenn, J.H., Tack, J., Barker, P.N., Lowe, E.S., Fleischmann, C., and Sostek, M. (2013). Multinational Association of Supportive Care in Cancer, Proceedings of the MASCC\/ISOO International Symposium on Supportive Care in Cancer, Berlin, Germany, 27\u201329 June 2013, John Wiley & Sons."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"e5","DOI":"10.1016\/j.jpainsymman.2018.09.024","article-title":"Challenges in Recruiting Patients to a Controlled Feasibility Study of a Drug for Opioid-Induced Constipation: Lessons from the Population With Advanced Cancer","volume":"57","author":"Bull","year":"2019","journal-title":"J. Pain Symptom Manag."},{"key":"ref_34","unstructured":"Critical Appraisal Skills Programme (2024, February 07). CASP Randomised Controlled Trial Checklist. Available online: https:\/\/casp-uk.net\/checklists\/casp-rct-randomised-controlled-trial-checklist-fillable.pdf."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1111\/1759-7714.14557","article-title":"A retrospective study of the efficacy and safety of naldemedine for opioid-induced constipation in thoracic cancer patients","volume":"13","author":"Imai","year":"2022","journal-title":"Thorac. Cancer"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"697","DOI":"10.21037\/apm-22-1130","article-title":"Efficacy and safety of naldemedine treatment for opioid-induced constipation in gastrointestinal cancer: A retrospective analysis","volume":"12","author":"Nishiba","year":"2023","journal-title":"Ann. Palliat. Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1089\/jpm.2022.0495","article-title":"Efficacy and Safety of Naldemedine Administration for Opioid-Induced Constipation in Cancer Patients with Poor Performance Status","volume":"26","author":"Fujita","year":"2023","journal-title":"J. Palliat. Med."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1200\/JCO.2016.70.8453","article-title":"Phase IIb, Randomized, Double-Blind, Placebo-Controlled Study of Naldemedine for the Treatment of Opioid-Induced Constipation in Patients with Cancer","volume":"35","author":"Katakami","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"3859","DOI":"10.1200\/JCO.2017.73.0853","article-title":"Randomized Phase III and Extension Studies of Naldemedine in Patients with Opioid-Induced Constipation and Cancer","volume":"35","author":"Katakami","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1093\/annonc\/mdy118","article-title":"Randomized phase III and extension studies: Efficacy and impacts on quality of life of naldemedine in subjects with opioid-induced constipation and cancer","volume":"29","author":"Katakami","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"e000527","DOI":"10.1136\/esmoopen-2019-000527","article-title":"Safety and efficacy of naldemedine in cancer patients with opioid-induced constipation: A pooled, subgroup analysis of two randomised controlled studies","volume":"4","author":"Osaka","year":"2019","journal-title":"ESMO Open"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"3943","DOI":"10.1007\/s00520-022-06807-y","article-title":"Post-marketing surveillance of the safety and effectiveness of naldemedine in the management of opioid-induced constipation in patients with cancer pain in Japan","volume":"30","author":"Takata","year":"2022","journal-title":"Support. Care Cancer"},{"key":"ref_43","first-page":"e46090","article-title":"Real-World Evidence for the Safety and Effectiveness of Naldemedine in the Management of Opioid-Induced Constipation in Patients with Cancer Pain: Post-hoc Subgroup Analysis of Post-marketing Surveillance in Japan","volume":"15","author":"Naya","year":"2023","journal-title":"Cureus"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1136\/bmjspcare-2020-002249","article-title":"Efficacy of naloxegol on symptoms and quality of life related to opioid-induced constipation in patients with cancer: A 3-month follow-up analysis","volume":"11","year":"2021","journal-title":"BMJ Support. Palliat. Care"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"7577","DOI":"10.1007\/s00520-021-06299-2","article-title":"Effectiveness of naloxegol in patients with cancer pain suffering from opioid-induced constipation","volume":"29","author":"Lemaire","year":"2021","journal-title":"Support. Care Cancer"},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Davies, A., Cinieri, S., Dupoiron, D., Espa\u00f1a Fernandez, S., Leclerc, J., Montesarchio, V., Mystakidou, K., Serna, J., Tack, J., and on Behalf of the Nacasy Study Group (2022). A Prospective, Real-World, Multinational Study of Naloxegol for Patients with Cancer Pain Diagnosed with Opioid-Induced Constipation-The NACASY Study. Cancers, 14.","DOI":"10.3390\/cancers14051128"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"e318","DOI":"10.1136\/bmjspcare-2020-002816","article-title":"One-year efficacy and safety of naloxegol on symptoms and quality of life related to opioid-induced constipation in patients with cancer: KYONAL study","volume":"13","year":"2023","journal-title":"BMJ Support Palliat. Care"},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Tobben, D., Carpenter, S., Kolar, R., Merritt, T., Young, T., Hauser, P., and Collier, T. (2023). Naloxegol versus Methylnaltrexone for Opioid-Induced Constipation in Critically Ill Patients. Ann. Pharmacother., 10600280231205023.","DOI":"10.1177\/10600280231205023"},{"key":"ref_49","unstructured":"(2023, December 01). Naldemedine (SYMPROIC) Criteria for Use, February 2019 VA Pharmacy Benefits Management Services, Medical Advisory Panel, and VISN Pharmacist Executives, Available online: https:\/\/www.va.gov\/formularyadvisor\/DOC_PDF\/Naldemedine_SYMPROIC.pdf."},{"key":"ref_50","unstructured":"(2023, December 01). Naloxegol (MOVANTIK) Criteria for Use March 2018 VA Pharmacy Benefits Management Services, Medical Advisory Panel, and VISN Pharmacist Executives, Available online: https:\/\/www.pbm.va.gov\/."}],"container-title":["Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2226-4787\/12\/2\/48\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:10:03Z","timestamp":1760105403000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2226-4787\/12\/2\/48"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,6]]},"references-count":50,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,4]]}},"alternative-id":["pharmacy12020048"],"URL":"https:\/\/doi.org\/10.3390\/pharmacy12020048","relation":{},"ISSN":["2226-4787"],"issn-type":[{"value":"2226-4787","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,6]]}}}